Covalon Technologies (CVE:COV) Reaches New 1-Year Low – Should You Sell?

Covalon Technologies Ltd. (CVE:COV)’s stock price hit a new 52-week low during mid-day trading on Thursday . The stock traded as low as C$1.59 and last traded at C$1.61, with a volume of 12522 shares traded. The stock had previously closed at C$1.63.

Covalon Technologies Stock Performance

The stock has a market cap of C$44.14 million, a P/E ratio of 23.00 and a beta of 0.82. The firm’s 50-day moving average is C$1.77 and its two-hundred day moving average is C$2.08. The company has a quick ratio of 6.45, a current ratio of 7.27 and a debt-to-equity ratio of 3.28.

About Covalon Technologies

Covalon Technologies Ltd. engages in the research, development, manufacturing, and marketing of medical products in infection management, advanced wound care, and surgical procedure areas in the United States, Canada, the Middle East, Asia, Latin America, and internationally. The company's platform technologies comprise collagen matrix platform that is used to manufacture a family of products to treat chronic and infected wounds, including diabetic ulcers, pressure ulcers, venous ulcers, donor and graft sites, traumatic wounds healing by secondary intention, dehisced surgical wounds, and first and second degree burns; and antimicrobial silicone adhesive platform, which is used for family of pre and post-surgical, and vascular access products that are designed to kill bacteria or yeast that comes into contact with the antimicrobial silicone providing broad-spectrum antimicrobial activity.